drugset / Trial / NCT00610493

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

NCT00610493

Phase 1 Completed 193 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of Avastin (bevacizumab) and Torisel (temsirolimus) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety of this drug combination will also be studied.

Timeline

Start
2008-01-25
Primary completion
2017-11-28
Completion
2017-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Subject Temsirolimus Small molecule 5 mg Intravenous

Indications

No indication recorded.